Sanofi CEO: Our pipeline is in the top 5

Sanofi CEO Chris Viehbacher

Despite the recent FDA rebuke of the blockbuster hopeful Lemtrada, Sanofi ($SNY) CEO Chris Viehbacher believes his company is poised to cash in on "a whole raft of new products" in the coming years. In an interview with Bloomberg, Viehbacher highlighted Sanofi's programs in PCSK9, arthritis and RNAi, saying the French giant is on the upswing of some promising innovations. "We've got the patent cliff behind us, and we've actually got a pretty robust pipeline," he said. "I actually believe we have one of the top 5 pipelines in the industry today." Video interview

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.